M. Gutiérrez

发表

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

Andreas Makris, Susan G. Hilsenbeck, Frederick L. Baehner, 2008, Breast Cancer Research and Treatment.

Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles

David L Waning, Meijing Wang, L. Plotkin, 2019, Cancers.

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Syed Mohsin, Susan G Hilsenbeck, S. Hilsenbeck, 2003, The Lancet.

Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

Jeffrey M. Rosen, Charles M. Perou, Susan G. Hilsenbeck, 2009, Proceedings of the National Academy of Sciences.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

S. Hilsenbeck, R. Schiff, Jenny C. Chang, 2005, Nature Clinical Practice Oncology.

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

M. Gutiérrez, E. Brain, J. Gligorov, 2010, Journal of Translational Medicine.

Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.

M. Campone, G. Romieu, F. Bidard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

M. Campone, G. Romieu, J. Pierga, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy.

M. Tubiana-Hulin, M. Gutiérrez, E. Brain, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative Carcino-embryonic Antigen and Carbohydrate Antigen 19-9 Serum Levels: Which Usefulness in Localised Colorectal Cancer?

M. Gutiérrez, E. Brain, S. Ahid, 2010 .

Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

I. Durand-zaleski, P. Cottu, M. Gutiérrez, 2013, BMC Health Services Research.

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.

R. Schiff, M. Dowsett, D. Allred, 2005, Endocrine-related cancer.

Long term response to erlotinib in a patient with recurrent vulvar carcinoma: Case report and review of literature.

M. Gutiérrez, E. Brain, H. Errihani, 2012, Gynecologic oncology case reports.

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

M. Gutiérrez, E. Mouret‐Fourme, P. Chérel, 2011, BMC Cancer.

Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration

M. Gutiérrez, G. Paintaud, C. Bonneau, 2021, Clinical pharmacology and therapeutics.

Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.

P. Fisher, J. Schlom, M. Gutiérrez, 1989, Anticancer research.

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

R. Schiff, M. Dowsett, D. Allred, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

S. Hilsenbeck, R. Schiff, Jenny C. Chang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.

S. Taillibert, O. Trédan, V. Diéras, 2018, European journal of cancer.

Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence

D. Edwards, S. Hilsenbeck, S. Oesterreich, 2012, Breast Cancer Research and Treatment.

Brain Metastases from Breast Cancer: Recursive Partitioning Analysis of Prognostic Factors Including Molecular Subtypes and Treatment

M. Gutiérrez, E. Mouret‐Fourme, C. Massard, 2010 .

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

M. Campone, G. Romieu, J. Pierga, 2013, The Lancet. Oncology.

Renal Cell Carcinoma with Gastric Metastases

M. Gutiérrez, H. Errihani, E. Mitry, 2012, Journal of Gastrointestinal Cancer.

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

R. Schiff, C. Creighton, S. Batra, 2012, Breast Cancer Research and Treatment.

Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment

M. Gutiérrez, E. Mouret‐Fourme, C. Massard, 2011, Journal of Neuro-Oncology.

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.

Syed Mohsin, Susan G Hilsenbeck, Michael T Lewis, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin.

M. Gutiérrez, P. Pautier, C. Lhommé, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.

S. Hilsenbeck, Jenny C. Chang, R. Elledge, 2003, Clinical breast cancer.

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers

S. Hilsenbeck, Jenny C. Chang, R. Elledge, 2005, Breast Cancer Research and Treatment.

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

J. Blay, A. Lluch, S. Verma, 2014, BMC Cancer.

Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis.

S. Vacher, S. Taillibert, O. Trédan, 2022, Neuro-oncology.

Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.

J. Blay, A. Lluch, S. Verma, 2009 .

PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC).

R. Bernards, H. Horlings, Jenny C. Chang, 2009 .

P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

M. Campone, G. Romieu, F. Bidard, 2011 .